Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Song, A. Carracedo, L. Salmena, S. Song, Ainara Egia, Marcos Malumbres, P. Pandolfi (2011)
Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex in a Phosphatase-Independent MannerCell, 144
Mohsin (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersJ Clin Oncol, 23
Sheng Chen, Can-ming Chen, Kexin Yu, R. Zhou, Z. Shao (2012)
Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast CancerAnnals of Surgical Oncology, 19
M. Dowsett, T. Nielsen, R. A’Hern, J. Bartlett, R. Coombes, J. Cuzick, M. Ellis, N. Henry, J. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, Ljudmila Prudkin, M. Regan, J. Salter, C. Sotiriou, I. Smith, G. Viale, J. Zujewski, D. Hayes (2011)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.Journal of the National Cancer Institute, 103 22
V. Rusch, E. Baldini, R. Bueno, M. Perrot, R. Flores, S. Hasegawa, W. Klepetko, L. Krug, L. Lang-Lazdunski, H. Pass, W. Weder, D. Sugarbaker (2013)
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.The Journal of thoracic and cardiovascular surgery, 145 4
M. Krismann, K. Müller, M. Jaworska, G. Johnen (2000)
Severe chromosomal aberrations in pleural mesotheliomas with unusual mesodermal features. Comparative genomic hybridization evidence for a mesothelioma subgroup.The Journal of molecular diagnostics : JMD, 2 4
M. Hinterberger, T. Reineke, M. Storz, W. Weder, P. Vogt, H. Moch (2007)
D2-40 and calretinin—a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiationModern Pathology, 20
L. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, Xiaomei Wang, Jennifer Yu, P. Malmström, M. Mansukhani, J. Enoksson, H. Hibshoosh, Å. Borg, R. Parsons (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.Cancer research, 65 7
C. Richardson, S. Schalm, J. Blenis (2004)
PI3-kinase and TOR: PIKTORing cell growth.Seminars in cell & developmental biology, 15 2
W. Shen, A. Balajee, Jianli Wang, Hong Wu, C. Eng, P. Pandolfi, Yuxin Yin (2007)
Essential Role for Nuclear PTEN in Maintaining Chromosomal IntegrityCell, 128
T. Beer, T. Beer, R. Buchanan, R. Buchanan, Alan Matthews, Alan Matthews, R. Stradling, R. Stradling, N. Pullinger, N. Pullinger, R. Pethybridge, R. Pethybridge (1998)
Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype.Human pathology, 29 3
S. Cedres, S. Cedres, Maria Montero, P. Martínez, P. Martínez, Alex Martínez, V. Rodríguez-Freixinós, D. Torrejon, A. Gabaldón, M. Salcedo, S. Cajal, E. Felip (2012)
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).Lung cancer, 77 1
A. Bader, P. Vogt (2004)
An essential role for protein synthesis in oncogenic cellular transformationOncogene, 23
Eugenio Leonardo, Fabrizio Zanconati, D. Bonifacio, L. Bonito (2001)
Immunohistochemical MIB-1 and p27kip1 as prognostic factors in pleural mesothelioma.Pathology, research and practice, 197 4
V. Agarwal, A. Campbell, K. Beaumont, L. Cawkwell, M. Lind (2013)
PTEN protein expression in malignant pleural mesotheliomaTumor Biology, 34
Roy Sidi, G. Pasello, I. Opitz, A. Soltermann, M. Tutic, H. Rehrauer, W. Weder, R. Stahel, E. Felley-Bosco (2011)
Induction of senescence markers after neo-adjuvant chemotherapy of malignant pleural mesothelioma and association with clinical outcome: an exploratory analysis.European journal of cancer, 47 2
C. Young, Andrew Lewis, Michael Rudolph, Marisa Ruehle, M. Jackman, U. Yun, O. Ilkun, R. Pereira, E. Abel, S. Anderson, A. Welm (2011)
Modulation of Glucose Transporter 1 (GLUT1) Expression Levels Alters Mouse Mammary Tumor Cell Growth In Vitro and In VivoPLoS ONE, 6
Kwok-kin Wong, J. Engelman, L. Cantley (2010)
Targeting the PI3K signaling pathway in cancer.Current opinion in genetics & development, 20 1
C. Bartholomeusz, A. González-Angulo (2012)
Targeting the PI3K signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 16
Jihyun Chung, Michael Ostrowski, T. Romigh, T. Minaguchi, K. Waite, C. Eng (2006)
The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation.Human molecular genetics, 15 17
D. Barbone, Tsung-Ming Yang, J. Morgan, G. Gaudino, C. Broaddus (2008)
Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids*Journal of Biological Chemistry, 283
H. Sawai, Akira Yasuda, N. Ochi, Jiachi Ma, Y. Matsuo, T. Wakasugi, Hiroki Takahashi, H. Funahashi, Mikinori Sato, H. Takeyama (2008)
Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survivalBMC Gastroenterology, 8
Song (2012)
The functions and regulation of the PTEN tumour suppressorNat Rev Mol Cell Biol, 13
L. Willems, J. Tamburini, N. Chapuis, C. Lacombe, P. Mayeux, D. Bouscary (2012)
PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted TherapiesCurrent Oncology Reports, 14
D. Branscheid, S. Krysa, E. Bauer, H. Bülzebruck, Joachim Schirren (1991)
Diagnostic and therapeutic strategy in malignant pleural mesothelioma.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 5 9
B. Robinson, R. Lake (2005)
Advances in malignant mesothelioma.The New England journal of medicine, 353 15
K. Sheppard, K. Kinross, B. Solomon, R. Pearson, W. Phillips (2012)
Targeting PI3 kinase/AKT/mTOR signaling in cancer.Critical reviews in oncogenesis, 17 1
A. Korshunov, R. Sycheva, S. Gorelyshev, A. Golanov (2005)
Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhoodModern Pathology, 18
W. Weder, R. Stahel, J. Bernhard, S. Bodis, P. Vogt, P. Ballabeni, D. Lardinois, D. Betticher, R. Schmid, R. Stupp, H. Ris, M. Jermann, W. Mingrone, A. Roth, A. Spiliopoulos (2007)
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.Annals of oncology : official journal of the European Society for Medical Oncology, 18 7
H. Suzuki, D. Freije, D. Nusskern, K. Okami, P. Cairns, D. Sidransky, W. Isaacs, G. Bova (1998)
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.Cancer research, 58 2
J. Engelman (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 9
W. Lim, W. Zhang, C. Miller, J. Watters, Feng Gao, A. Viswanathan, R. Govindan, H. McLeod (2007)
PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer.Oncology reports, 17 4
B. Carter (2012)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupYearbook of Pathology and Laboratory Medicine, 2012
Robinson (2005)
Malignant mesotheliomaLancet, 366
M. Song, L. Salmena, P. Pandolfi (2012)
The functions and regulation of the PTEN tumour suppressorNature Reviews Molecular Cell Biology, 13
Brian Magnuson, B. Ekim, D. Fingar (2012)
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.The Biochemical journal, 441 1
T. Lotan, B. Gurel, S. Sutcliffe, David Esopi, Wennuan Liu, Jianfeng Xu, J. Hicks, B. Park, E. Humphreys, A. Partin, Misop Han, G. Netto, W. Isaacs, A. Marzo (2011)
PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer PatientsClinical Cancer Research, 17
M. Perrot, R. Feld, B. Cho, A. Bezjak, M. Anraku, R. Burkes, H. Roberts, M. Tsao, N. Leighl, S. Keshavjee, Michael Johnston (2009)
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 9
J. Fata, Shawon Debnath, E. Jenkins, M. Fournier (2012)
Nongenomic Mechanisms of PTEN RegulationInternational Journal of Cell Biology, 2012
C. Cao, D. Tian, C. Manganas, P. Matthews, T. Yan (2012)
Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.Annals of cardiothoracic surgery, 1 4
L. Stayner, L. Welch, R. Lemen (2013)
The worldwide pandemic of asbestos-related diseases.Annual review of public health, 34
S. Mohsin, H. Weiss, M. Gutiérrez, G. Chamness, R. Schiff, M. DiGiovanna, Chun-xia Wang, S. Hilsenbeck, C. Osborne, D. Allred, R. Elledge, Jenny Chang (2005)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancersNature Clinical Practice Oncology, 2
A. Alberts, G. Falkson, L. Goedhals, D. Vorobiof, C. Merwe (1988)
Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 3
K. Kadota, Kei Suzuki, C. Colovos, C. Sima, V. Rusch, W. Travis, P. Adusumilli (2012)
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesotheliomaModern Pathology, 25
M. Yoshimoto, I. Cunha, R. Coudry, F. Fonseca, C. Torres, F. Soares, J. Squire, J. Squire (2007)
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcomeBritish Journal of Cancer, 97
I. Opitz, A. Soltermann, Martin Abaecherli, M. Hinterberger, N. Probst-Hensch, R. Stahel, H. Moch, W. Weder (2008)
PTEN expression is a strong predictor of survival in mesothelioma patients.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 33 3
Jill Stahl, M. Cheung, Arati Sharma, Nishit Trivedi, Sumathi Shanmugam, G. Robertson (2003)
Loss of PTEN promotes tumor development in malignant melanoma.Cancer research, 63 11
J. Schildge, D. Kaiser, H. Henß, H. Fiebig, H. Ortlieb (1989)
[Prognostic factors in diffuse malignant mesothelioma of the pleura].Pneumologie, 43 11
J. Arranz, M. Barón, M. Paredes (1994)
[Malignant mesothelioma].Medicina clinica, 102 14
M. Byrne, A. Nowak (2004)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.Annals of oncology : official journal of the European Society for Medical Oncology, 15 2
S. Planchon, K. Waite, C. Eng (2008)
The nuclear affairs of PTENJournal of Cell Science, 121
Comin, Anichini, Boddi, Novelli, Dini (2000)
MIB‐1 proliferation index correlates with survival in pleural malignant mesotheliomaHistopathology, 36
ORIGINAL ARTICLE PI3K/mTOR Signaling in Mesothelioma Patients Treated with Induction Chemotherapy Followed by Extrapleural Pneumonectomy Byron K.Y. Bitanihirwe, PhD,* Mayura Meerang, PhD,* Martina Friess, VMD,* Alex Soltermann, MD,† Lukas Frischknecht, MD,† Svenja Thies, MD,† Emanuela Felley-Bosco, PhD,‡ Ming-Sound Tsao, MD,§ Ghassan Allo, MD,§ Marc de Perrot, MD,║ Burkhardt Seifert, PhD,¶ Holger Moch, MD,† Rolf Stahel MD,‡ Walter Weder MD,* and Isabelle Opitz, MD* expression in samples before and after induction chemotherapy of Introduction: The prognostic significance of activity biomarkers cohort 1 revealed that decreased cytoplasmic PTEN and increased within the phosphatidylinositol 3-kinase (PI3K)/mammalian target phospho-mTOR expression was associated with a worse OAS of rapamycin (mTOR) signaling pathway was assessed in two inde- (p = 0.04 and p = 0.03, respectively). pendent cohorts of malignant pleural mesothelioma (MPM) patients Conclusions: These novel data reveal a prognostic significance of uniformly treated with a multimodal approach. We specifically expression changes of PI3K/mTOR pathway components during assessed expression signatures in a unique set of pre- and postchemo- induction chemotherapy if confirmed in other patient cohorts and therapy tumor samples. support the growing evidence to target the PI3K/mTOR pathway in Methods: Biomarker expression was assessed in samples of two the treatment of MPM. independent cohorts of 107 (cohort 1) and 46 (cohort 2) MPM
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Feb 1, 2014
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.